Top Industry Leaders in the Soft Tissue Sarcoma Market
Latest Soft Tissue Sarcoma Companies Updates:
Incyte Corporation acquires Epizyme: This December 2023 acquisition strengthens Incyte's oncology pipeline, adding Epizyme's targeted therapy for STS with EZH2 mutations.
Bayer acquires BlueRock Therapeutics: This October 2023 acquisition expands Bayer's cell and gene therapy portfolio, potentially leading to new treatment options for STS in the future.
This December 2023 news demonstrates FT515's potential in treating advanced STS with FGFR3 mutations, opening doors for further clinical development.
FDA grants Breakthrough Therapy Designation to larotrectinib (Loxo Oncology): This January 2024 designation expedites the development and review process for larotrectinib in patients with STS harboring NTRK gene fusions.
List of Soft Tissue Sarcoma Key companies in the market:
- GlaxoSmithKline plc (U.K)
- Eli Lilly and Company (U.S.)
- Pfizer Inc. (U.S.)
- Bristol-Myers Squibb (U.S.)
- Switzerland) Inc. (U.S.)
- Johnson & Johnson Services Inc. (U.S.)